We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00848016
First Posted: February 20, 2009
Last Update Posted: May 7, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Cancer Institute (NCI)
Results First Submitted: January 6, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Recurrent Adrenocortical Carcinoma
Stage III Adrenocortical Carcinoma
Stage IV Adrenocortical Carcinoma
Intervention: Drug: R-(-)-gossypol acetic acid

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
This study opened on 3/17/2009 and accrued 29 participants before being permanently closed 8/03/2011.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
All 29 participants are off treatment, and all participants are evaluable for response and for adverse responses.

Reporting Groups
  Description
Treatment (R-(-)-Gossypol Acetic Acid) Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Participant Flow:   Overall Study
    Treatment (R-(-)-Gossypol Acetic Acid)
STARTED   29 
COMPLETED   29 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Treatment (R-(-)-Gossypol Acetic Acid) Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Baseline Measures
   Treatment (R-(-)-Gossypol Acetic Acid) 
Overall Participants Analyzed 
[Units: Participants]
 29 
Age 
[Units: Years]
Median (Full Range)
 50 
 (28 to 76) 
Gender 
[Units: Participants]
 
Female   15 
Male   14 
Region of Enrollment 
[Units: Participants]
 
United States   29 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response Evaluation Criteria In Solid Tumors (RECIST) Criteria   [ Time Frame: Up to 2 years ]

2.  Secondary:   Overall Survival   [ Time Frame: From registration to date of last follow-up or death due to any cause, assessed up to 2 years ]

3.  Secondary:   Progression-free Survival   [ Time Frame: From registration to progression or death, whichever occurs first, up to 2 years. ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Michael E. Menefee, M.D.
Organization: Mayo Clinic Cancer Center
e-mail: menefee.michael@mayo.edu



Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00848016     History of Changes
Other Study ID Numbers: NCI-2009-01160
MC0771
8035
CDR0000635024
N01CM00070 ( U.S. NIH Grant/Contract )
N01CM00038 ( U.S. NIH Grant/Contract )
First Submitted: February 19, 2009
First Posted: February 20, 2009
Results First Submitted: January 6, 2014
Results First Posted: February 21, 2014
Last Update Posted: May 7, 2014